[Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
TIL of 24 patients with malignant pleural effusions were induced and expanded in vitro. The phenotype of lymphocytes IL2R, NK cytotoxicity activity were analysed in fresh and activated TIL. CEA and cytology of malignant pleural effusion were detected before and after treatment with TIL/rIL2. The results indicated: CD4.CD8.IL2R, NK activity increased markedly, CEA level decreased in all of the patients, tumor cells disappeared in some patients. The pleural effusion disappeared in 63%. The total effective rate of the treatment is 79%. No serious toxicity and side effects were found in 1 to 6 months period of following-up after treatment.
Han
B
B
Shanghai Chest Hospital.
Jia
Y
Y
Zhou
M
M
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins